Castle Biosciences Inc
NASDAQ:CSTL
| Market Cap (Intraday) | 1.28B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $64.09 |
| 50-Day MA | $69.47 |
| 200-Day MA | $70.06 |
Castle Biosciences Inc Stock, NASDAQ:CSTL
820 South Friendswood Drive, Suite 201, Friendswood, Texas 77546
United States of America
Phone: +1.866.788.9007
Number of Employees: 201
Description
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.